Veteran life-sciences executive and investor focused on biotech strategy, clinical-stage assets and translational research commercialization. Neil Greenspan brings operating and advisory experience across therapeutics development, partnering and capital formation, often supporting seed-to-growth equity rounds and licensing transactions. Background blends scientific leadership with board and advisory roles, informing go-to-market assessments, pipeline valuation and risk-adjusted investment theses. Active in deal sourcing, due diligence and cross-disciplinary management of R&D portfolios, with experience working alongside institutional investors and corporate partners to advance clinical programs. Market-relevant strengths include technical vetting of targets, structuring collaborative alliances and advising on exit pathways for early-stage life-science ventures.
Veteran life-sciences executive and investor focused on biotech strategy, clinical-stage assets and translational research commercialization. Neil Greenspan brings operating and advisory experience across therapeutics development, partnering and capital formation, often supporting seed-to-growth equity rounds and licensing transactions. Background blends scientific leadership with board and advisory roles, informing go-to-market assessments, pipeline valuation and risk-adjusted investment theses. Active in deal sourcing, due diligence and cross-disciplinary management of R&D portfolios, with experience working alongside institutional investors and corporate partners to advance clinical programs. Market-relevant strengths include technical vetting of targets, structuring collaborative alliances and advising on exit pathways for early-stage life-science ventures.
Brings a science-led, active-investor approach to early and clinical-stage biotech, prioritizing translational assets with clear de-risking pathways and demonstrable mechanistic validation. Capital allocation favors seed-to-growth equity and structured licensing where technical due diligence, milestone-driven financing and partner syndication reduce binary clinical risk. Investment horizon is medium-to-long, focused on value creation through catalytic data readouts, alliance formation and disciplined portfolio construction. Decisions emphasize deep technical vetting, pragmatic go‑to‑market planning and exit strategies aligned with strategic acquirers and public markets.
Brings a science-led, active-investor approach to early and clinical-stage biotech, prioritizing translational assets with clear de-risking pathways and demonstrable mechanistic validation. Capital allocation favors seed-to-growth equity and structured licensing where technical due diligence, milestone-driven financing and partner syndication reduce binary clinical risk. Investment horizon is medium-to-long, focused on value creation through catalytic data readouts, alliance formation and disciplined portfolio construction. Decisions emphasize deep technical vetting, pragmatic go‑to‑market planning and exit strategies aligned with strategic acquirers and public markets.
| Trades 1915 | Longs Won 1358/1915 70% | Profit Factor 7.2 |
| Profitability | Shorts Won 0/0 0% | Standard Deviation $535,547.09 |
| Average Win $140,598.41 | Best Trade (Jul 10) $8.51M | Sharpe Ratio -10.24 |
| Average Loss -$47,615.06 | Worst Trade (Jul 13) -$5.82M | Z-Score 13.16 (100%) |
| Commissions $0 | Avg. Trade Length 1y 1m 3w 6d | Expectancy $85,854.34 |
| Loss Size | 100% | 90% | 80% | 70% | 60% | 50% | 40% | 30% | 20% | 10% |
| Probability of Loss | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% |
| Consecutive Losing Trades | 9,346 | 8,411 | 7,477 | 6,542 | 5,607 | 4,673 | 3,738 | 2,804 | 1,869 | 935 |